Mylan has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral drug Avonza, a treatment recommended by WHO as an alternative first-line regimen for people treated for HIV/AIDS.
Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets.
According to Mylan President Rajiv Malik, Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. Additionally, Mylan is the first to offer this combination in India.
Read the Street Insider coverage